The E3 Ubiquitin Protein Ligase LINCR Amplifies the TLR-Mediated Signals through Direct Degradation of MKP1
Cells · 2024
DOI: 10.3390/cells13080687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Takumi Yokosawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan. Hauptthemen laut MEDLINE: Dual Specificity Phosphatase 1, Toll-Like Receptors, Ubiquitin-Protein Ligases, Ubiquitination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI, Takeda Science Foundation.
Abstract (Originalsprache)
Toll-like receptors (TLRs) induce innate immune responses through activation of intracellular signaling pathways, such as MAP kinase and NF-κB signaling pathways, and play an important role in host defense against bacterial or viral infections. Meanwhile, excessive activation of TLR signaling leads to a variety of inflammatory disorders, including autoimmune diseases. TLR signaling is therefore strictly controlled to balance optimal immune response and inflammation. However, its balancing mechanisms are not fully understood. In this study, we identified the E3 ubiquitin ligase LINCR/ NEURL3 as a critical regulator of TLR signaling. In LINCR-deficient cells, the sustained activation of JNK and p38 MAPKs induced by the agonists for TLR3, TLR4, and TLR5, was clearly attenuated. Consistent with these observations, TLR-induced production of a series of inflammatory cytokines was significantly attenuated, suggesting that LINCR positively regulates innate immune responses by promoting the activation of JNK and p38. Interestingly, our further mechanistic study identified MAPK phosphatase-1 (MKP1), a negative regulator of MAP kinases, as a ubiquitination target of LINCR. Thus, our results demonstrate that TLRs fine-tune the activation of MAP kinase pathways by balancing LINCR (the positive regulator) and MKP1 (the negative regulator), which may contribute to the induction of optimal immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
ORCID-Profile: Yusuke Hirata, Takuya Noguchi, Atsushi Matsuzawa
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI
- Takeda Science Foundation
- Uehara Memorial Foundation
- Division for Interdisciplinary Advanced Research and Education (DIARE) Tohoku University
Zitieren
APA
Yokosawa, T., Miyagawa, S., Suzuki, W., Nada, Y., Hirata, Y., Noguchi, T., & Matsuzawa, A. (2024). The E3 Ubiquitin Protein Ligase LINCR Amplifies the TLR-Mediated Signals through Direct Degradation of MKP1. Cells. https://doi.org/10.3390/cells13080687
Vancouver
Yokosawa T, Miyagawa S, Suzuki W, Nada Y, Hirata Y, Noguchi T, et al. The E3 Ubiquitin Protein Ligase LINCR Amplifies the TLR-Mediated Signals through Direct Degradation of MKP1. Cells. 2024. doi:10.3390/cells13080687
BibTeX
@article{Yokosawa2024,
author = {Yokosawa, Takumi and Miyagawa, Sayoko and Suzuki, Wakana and Nada, Yuki and Hirata, Yusuke and Noguchi, Takuya and Matsuzawa, Atsushi},
title = {The E3 Ubiquitin Protein Ligase LINCR Amplifies the TLR-Mediated Signals through Direct Degradation of MKP1},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13080687}
}
EUVIMED